tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALLO Stock Latest News

Allogene Therapeutics Earnings Call: Progress Amid Challenges
Company AnnouncementsAllogene Therapeutics Earnings Call: Progress Amid Challenges
2d ago
ALLO
Allogene Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Allogene Therapeutics management to meet with Piper Sandler
8d ago
ALLO
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
PremiumCompany Announcements
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
18d ago
ALLO
Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics
PremiumRatings
Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics
19d ago
ALLO
Allogene Therapeutics Advances in CAR T Cell Therapy
PremiumCompany Announcements
Allogene Therapeutics Advances in CAR T Cell Therapy
20d ago
ALLO
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
PremiumThe FlyAllogene Therapeutics reports Q2 EPS (23c), consensus (27c)
20d ago
ALLO
Allogene Therapeutics options imply 16.7% move in share price post-earnings
Premium
The Fly
Allogene Therapeutics options imply 16.7% move in share price post-earnings
20d ago
ALLO
Options Volatility and Implied Earnings Moves Today, August 13, 2025
Premium
Market News
Options Volatility and Implied Earnings Moves Today, August 13, 2025
20d ago
OGI
ALLO
Is ALLO a Buy, Before Earnings?
PremiumPre-Earnings
Is ALLO a Buy, Before Earnings?
22d ago
ALLO
Strategic Adjustments and Technological Advancements Drive Buy Rating for Allogene Therapeutics
PremiumRatings
Strategic Adjustments and Technological Advancements Drive Buy Rating for Allogene Therapeutics
29d ago
ALLO
Allogene Therapeutics: Strategic Adjustments and Positive Interim Data Justify Buy Rating
PremiumRatings
Allogene Therapeutics: Strategic Adjustments and Positive Interim Data Justify Buy Rating
1M ago
ALLO
Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
PremiumThe Fly
Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan
1M ago
ALLO
Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
PremiumThe FlyAllogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
1M ago
ALLO
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
Premium
Company Announcements
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
1M ago
8K
ALLO
Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
Premium
The Fly
Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
1M ago
ALLO
Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment
PremiumCompany Announcements
Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment
1M ago
ALLO
Allogene Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Allogene Therapeutics management to meet with Piper Sandler
1M ago
ALLO
Allogene Therapeutics Holds Annual Stockholder Meeting
PremiumCompany Announcements
Allogene Therapeutics Holds Annual Stockholder Meeting
2M ago
8K
ALLO
Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
PremiumRatings
Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
3M ago
ALLO
Allogene Therapeutics provides updated Phase 1 TRAVERSE study of ALLO-316
PremiumThe FlyAllogene Therapeutics provides updated Phase 1 TRAVERSE study of ALLO-316
3M ago
ALLO
Allogene Therapeutics’ Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Allogene Therapeutics’ Earnings Call: Progress Amid Challenges
4M ago
ALLO
Allogene Therapeutics price target lowered to $4 from $8 at Citi
Premium
The Fly
Allogene Therapeutics price target lowered to $4 from $8 at Citi
4M ago
ALLO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >